Navigation Links
Manufacturing and Characterization of Therapeutic Exosomes

The era of using extracellular vesicles (EVs) and exosomes for regenerative medicine applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like cell culturing process to manufacture secreted EVs present in conditioned medium for clinical studies.

Dr. Travis Antes, head of analytical development at Capricor Therapeutics Inc., will be the speaker for this presentation. He will review the strategies for clinical scale EV manufacturing, characterization of surface phenotypes and RNA cargo, molecular tools available to characterize extracellular vesicles, as well as building a pipeline for successful QC of these EVs for use in the clinic.

Antes earned a doctorate in Molecular and Cell Biology from the University of Texas in Dallas. In 2016, he joined the faculty at Cedars-Sinai Heart Institute as an associate professor and also became the Head of Analytical Development for Capricor Therapeutics Inc. His current research involves the characterization and development of therapeutic exosomes for a variety of disease applications.

This is a LabRoots hosted webinar, sponsored by Miltenyi Biotec. The webinar will take place on September 6, 2017, beginning at 9:00 a.m. PDT, 12:00 p.m. EDT. To learn more about this webinar, discover the continuing education credits offered, or to register for free, click here.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of cardiac and other serious medical conditions. Capricor’s innovative technology builds upon a large body of scientific research and enables a novel approach to the treatment of diseases. They are one of the leading companies investigating the field of exosome science with plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas.

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Life Technologies to Invest $18 Million in Facility Expansion and Current Good Manufacturing Practice Compliance Plan
2. Professional Pricing Society Survey Reveals 12 Percent Gain in Manufacturing and Distribution Salaries, Indicating Growing Value of Pricing Expertise
3. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
4. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
5. Process Analytical Technology: The Future of Pharmaceutical Manufacturing is Now
6. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
7. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
8. AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business
9. Medical Manufacturing to Mountaineering: KMC Employees Take it to the Top
10. InstantGMP Announces Addition of Cost and Pricing Model to Electronic Batch Records in Their Manufacturing Execution System
11. PharmSource CMO-CDMO Database Expands Coverage to Include Approved Pharmaceutical Products: Intelligence Resource for Analyzing Bio/Pharmaceutical Contract Manufacturing
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):